09:04:15 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-04-05 Ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 Årsstämma 2024
2024-03-07 Bokslutskommuniké 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-03-31 Ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 Årsstämma 2023
2023-03-02 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-04-06 Ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 Årsstämma 2022
2022-03-02 Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden från onkologi till neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.
2023-12-01 08:00:00

Aiforia Technologies Plc, Company Release, December 1, 2023 09:00 a.m. EET. Aiforia Technologies Plc reinforces its Management Team to strengthen the implementation of the company's growth strategy. 

Panu Kauppila has been appointed Chief Product Officer and a member of the Management Team (previously Vice President of Product Management) as of 1.12.2023. He has been with the company since June 2022. Panu has played a key role in defining Aiforia's product portfolio and prioritizing product development. In particular, he has led the definition, development, and delivery of clinical product portfolio.

Panu has more than 25 years of experience in productization and management of innovation in the medical technology sector in international companies. Before Aiforia, he has worked at Philips as an international product development director for radiotherapy and also for digital pathology solutions. He graduated from the Helsinki University of Technology with a degree in Medical Physics and Technology.

"We are expanding the management team to bring product management more closely into strategic decision-making. Panu has a profound understanding of how scalable products can be built on top of a software platform for demanding preclinical and clinical use. Another strength he has is the ability to identify relevant trends in the market and use this knowledge in product development," says Jukka Tapaninen, CEO of Aiforia.

After the appointment, the composition of Aiforia's Management Team is as follows:

Jukka Tapaninen, Chief Executive Officer

Kaisa Helminen, Chief Operating Officer

Kari Pitkänen, Director of Business Development

Tuomas Ropponen, Chief Technology Officer

Veli-Matti Parkkonen, Chief Financial Officer

Thomas Westerling-Bui, Vice President of AI Solutions & Strategy

Panu Kauppila, Chief Product Officer

More detailed information on the members of the Management Team are available on the company's website at https://investors.aiforia.com/management-team.

Further inquiries

Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686 https://investors.aiforia.com/ 

Certified Adviser

UB Securities Ltd, tel. +358 9 25 380 225 

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.

Find out more at www.aiforia.com